Dr Luis Paz-Ares speaks to ecancer about the groundbreaking impact of T-cell engagers in treating small cell lung cancer (SCLC).

He details the impressive response rates and survivorship achieved so far in early phase trials and looks at how this innovative therapy activates the immune system, offering new hope for patients, particularly those with challenging SCLC presentations.

He concludes by noting that T-cell engagers are important for SCLC where very often there is a down regulation of MHC (Major Histocompatibility Complex) class 1. Therefore, it is a good mechanism for tumours where there is no initial T-cell activation.